MRUS250117P45000
- 2.20
- -1.09-33.13%
Merus Newsroom
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)
Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $73
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $97
Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations
Merus Price Target Raised to $97.00/Share From $89.00 by Citigroup
Merus Is Maintained at Buy by Citigroup
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
TD Cowen Maintains Merus(MRUS.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Merus Price Target Maintained With a $85.00/Share by Needham